Department of Dermatology, University Hospital of Liège, and University of Liège, Liège, Belgium.
Dermatology. 2012;224(3):251-6. doi: 10.1159/000338691. Epub 2012 Jun 1.
The incidence and severity of herpes zoster (HZ) appear increased in patients receiving tumor necrosis factor-α antagonists.
To study the incidence and clinical features of HZ in 1,220 patients (4,206 patient-years) receiving either adalimumab, etanercept, infliximab, rituximab or ustekinumab.
Twenty-two HZ cases were identified [1.26% of total cohort; adalimumab: 11/1,546 patient-years, incidence rate (IR) 7.1; etanercept: 4/789 patient-years, IR 5.1; rituximab: 1/168 patient-years, IR 5.2; ustekinumab: 2/37 patient-years, IR 53.5; infliximab: 4/1,666 patient-years, IR 2.4]. The time to event varied widely (1.5- 108 months). Extensive HZ was reported in 45 and 32% of the cases, respectively. Persistent postzoster neuralgia (PHN; >6 months) was observed in 5/20 patients.
The HZ incidence was 2.1-fold higher among patients over 60 years, compared with a reference population, although not statistically significant. Severe, multidermatomal HZ and persistent PHN were common.
肿瘤坏死因子-α 拮抗剂治疗患者的带状疱疹（HZ）发生率和严重程度似乎增加。
研究在接受阿达木单抗、依那西普、英夫利昔单抗、利妥昔单抗或乌司奴单抗治疗的 1220 名患者（4206 患者年）中 HZ 的发生率和临床特征。
共发现 22 例 HZ 病例[总队列的 1.26%；阿达木单抗：11/1546 患者年，发病率（IR）为 7.1；依那西普：4/789 患者年，IR 为 5.1；利妥昔单抗：1/168 患者年，IR 为 5.2；乌司奴单抗：2/37 患者年，IR 为 53.5；英夫利昔单抗：4/1666 患者年，IR 为 2.4]。发病时间差异很大（1.5-108 个月）。分别有 45%和 32%的病例报告了广泛的 HZ。20 例患者中有 5 例出现持续性带状疱疹后神经痛（PHN；>6 个月）。
与参考人群相比，60 岁以上患者的 HZ 发病率高 2.1 倍，但无统计学意义。严重的多节段 HZ 和持续性 PHN 很常见。
